Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Duration Varenicline for Smoking Relapse Prevention in Schizophrenia or Bipolar Disorder
NCT00621777Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2008
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of varenicline in nicotine dependence (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Rate of 7-day Point Prevalence Abstinence at the End of the Relapse Prevention Phase at 52 weeks. Started Feb 2008; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00621777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621777.